Wedbush Maintains Outperform on 2seventy bio, Lowers Price Target to $22
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has maintained an Outperform rating on 2seventy bio (NASDAQ:TSVT), but lowered the price target from $26 to $22.
July 28, 2023 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush has maintained an Outperform rating on 2seventy bio, but lowered the price target from $26 to $22.
The news is directly about 2seventy bio and is likely to influence investor sentiment. While the Outperform rating is positive, the lowering of the price target may create some uncertainty. However, as the rating remains positive, the overall impact on the stock price is expected to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100